Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab govitecan + pembrolizumab + cisplatin
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Sacituzumab govitecan + pembrolizumab + cisplatin** is an investigational triple combination regimen used in clinical trials for advanced or metastatic non-small-cell lung cancer (NSCLC) and potentially other solid tumors. - **Sacituzumab govitecan** is an antibody-drug conjugate targeting Trop-2, delivering the cytotoxic payload SN-38 to tumor cells. - **Pembrolizumab** is a monoclonal antibody checkpoint inhibitor targeting PD-1, enhancing antitumor immune response. - **Cisplatin** is a platinum-based chemotherapeutic agent causing DNA crosslinking and apoptosis in cancer cells. The combination is being evaluated for synergistic antitumor activity where antibody-drug conjugate, immunotherapy, and chemotherapy may improve efficacy over monotherapies. The primary indications under investigation include advanced/metastatic NSCLC (without actionable genomic alterations) and potentially other solid tumors.
- Other names
- sacituzumab govitecan-hziySGpembrolizumab (MK-3475)cis-diamminedichloroplatinum(II)
02
Targets
TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on sacituzumab govitecan + pembrolizumab + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab govitecan + pembrolizumab + cisplatin.